SAM
VYGR icon

Shell Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Shell Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-86,068
Closed -$405K – 1558
2021
Q1 		$405K Buy
86,068
+42,047
+96% +$287K 0.01% 939
2020
Q4 		$315K Buy
44,021
+33,055
+301% +$318K 0.01% 982
2020
Q3 		$117K Hold
10,966
– – ﹤0.01% 1143
2020
Q2 		$138K Buy
+10,966
New +$128K ﹤0.01% 1106

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Shell Asset Management's VYGR Position: Q2 2021 in Review

Shell Asset Management sold out of Voyager Therapeutics (VYGR) in Q2 2021, closing a stake of 86,068 shares — an estimated $405K sold.

Shell Asset Management first reported a position in VYGR in Q2 2020 and held it in 4 quarters. The position peaked at $405K in Q1 2021. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2021.

  • Shell Asset Management reported no remaining Voyager Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Shell Asset Management sold 86,068 Voyager Therapeutics shares in Q2 2021, an estimated $405K.
  • Shell Asset Management first reported a position in Voyager Therapeutics in Q2 2020 and held it in 4 quarters.
  • Shell Asset Management's Voyager Therapeutics position peaked at $405K in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2021.

Based on Shell Asset Management's 13F filing for Q2 2021, filed 12 Aug 2021.